Systemic Lupus Erythematosus (SLE)

Understand

Overview

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease in which the immune system produces autoantibodies directed against components of the body's own cells — primarily nuclear material — leading to immune complex deposition and chronic inflammation across multiple, often seemingly unrelated tissues: skin, joints, kidneys, nervous system, heart, lungs, and blood. Unlike autoimmune diseases confined to a single organ, such as Hashimoto's disease, which attacks only the thyroid, lupus is by definition a systemic disease — the same underlying immune process can present completely differently in two different patients.

The epidemiology of lupus is among the most striking in all of rheumatology in terms of its sex and ethnic distribution. A global epidemiological review by Barber and colleagues from 2021 indicates that incidence in Western populations typically runs from a few to over a dozen cases per 100,000 people per year, with a clear, consistent female predominance — among women of reproductive age, the ratio of cases reaches as high as 9:1 in favor of women, though this difference narrows before puberty and after menopause, strongly suggesting a modulating role of sex hormones on immune activity. The disease also occurs significantly more often, and typically runs a more severe course, in Black, Asian, and Hispanic populations compared with white populations, pointing to a substantial genetic component — though genetic predisposition alone rarely suffices without an additional environmental trigger that sets off the autoimmune process.

The clinical picture of lupus is remarkably variable between patients, which is one of the main reasons why, from the first nonspecific symptoms (chronic fatigue, low-grade fevers, joint pain) to an actual diagnosis, several years typically pass. The most recognizable, though not universal, symptom is a butterfly-shaped rash across the cheeks and nose that worsens with UV exposure — photosensitivity affects as many as roughly 70% of people with lupus and is one of the best-documented, concrete triggers of disease flares. Beyond the skin, the disease can involve the joints (pain and swelling, usually symmetric, without the lasting deformities typical of rheumatoid arthritis), the kidneys (lupus nephritis, often asymptomatic in its early stage), the nervous system, blood (anemia, low platelet counts), and the heart and lungs (inflammation of the serous membranes).

Diagnosing lupus never rests on a single lab test, but on a combined, formally weighted assessment of clinical symptoms and immunological findings. The current ACR/EULAR 2019 classification criteria, which replaced the earlier, less sensitive 1997 ACR criteria, require a positive antinuclear antibody (ANA) titer at least once in the patient's history as an entry criterion — these antibodies are detected in over 95% of lupus patients, though a positive ANA at a low titer also occurs in part of the healthy population and isn't decisive on its own. Once this entry condition is met, seven clinical domains (including skin, joint, kidney, neuropsychiatric, and hematologic) and three immunological domains are scored, each positive item carrying its own weight — classification as lupus requires a total of at least 10 points, and in the validation study these criteria achieved 96.1% sensitivity and 93.4% specificity.

Lupus nephritis deserves particular attention, since it's one of the complications with the greatest impact on long-term prognosis, and its early stages can be entirely asymptomatic — without pain, swelling, or any visible change in urine appearance. The only early warning sign is often an abnormal result on a routine urine test (protein or blood in the urine), performed regularly for exactly this reason, even in the complete absence of symptoms — the earlier immunosuppressive treatment begins in this situation, the better the prognosis for preserving kidney function.

Treatment for lupus is far more effective today than it was two or three decades ago, and its cornerstone remains hydroxychloroquine — an antimalarial drug used in rheumatology for decades, recommended today for nearly all lupus patients without contraindications. This isn't purely symptomatic treatment: an analysis of data from the multiethnic LUMINA cohort, conducted by Alarcón and colleagues, found that hydroxychloroquine use was associated with a significantly lower risk of death among lupus patients, making it one of the few rheumatology drugs with concrete survival data behind it, not just symptom control.

This entry focuses on the mechanism, epidemiology, formal diagnosis, and core treatment principles of the disease as an encyclopedic introduction to the topic. Day-to-day life with lupus, the full range of flare triggers, the detailed treatment ladder from hydroxychloroquine to biologics, and the warning signs that call for urgent medical attention are covered in much greater depth in our article on the symptoms and treatment of systemic lupus erythematosus, worth reading once you have this general picture of the disease.